BioWorld

Nov. 3, 2003

View Archived Issues

CV Therapeutics Stock Drops On Ranexa Approvable Letter

CV Therapeutics Inc. received a mixed bag of news related to Ranexa, its lead compound for chronic angina, and investors took the news badly as the company's stock slipped 21.7 percent Friday. (BioWorld Today) Read More

Fast Action Urged To Rescue Reef Cone Snails From Global Warming, To Garner Rich Trove Of Medicines

Read More

With Venter On Board, Ionian Has Biothreat Detection Focus

Read More

Other News To Note

Read More